{
  "id": "61f93c38882a024a1000004b",
  "type": "yesno",
  "question": "Can Isradipine slow progression of Early Parkinson Disease?",
  "ideal_answer": "No. In a multicenter, randomized, parallel-group, double-blind, placebo-controlled trial Isradipine did not slow progression of Early Parkinson Disease.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32227247",
    "http://www.ncbi.nlm.nih.gov/pubmed/34766657",
    "http://www.ncbi.nlm.nih.gov/pubmed/33460320",
    "http://www.ncbi.nlm.nih.gov/pubmed/33716705"
  ],
  "snippets": [
    {
      "text": "Adjusted least-squares mean changes in total UPDRS score in the antiparkinson medication ON state over 36 months for isradipine and placebo recipients were 2.99 (95% CI, 0.95 to 5.03) points versus 3.26 (CI, 1.25 to 5.26) points, respectively, with a treatment effect of -0.27 (CI, -3.02 to 2.48) point (P\u00a0= 0.85).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32227247",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusion: Long-term treatment with immediate-release isradipine did not slow the clinical progression of early-stage PD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32227247",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ONS: These results are consistent with the recent secondary analysis of the STEADY-PD III clinical trial-suggesting that clinically attainable brain exposure to isradipine may slow early-stage PD progression. \u00a9 2021 ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34766657",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These findings suggest that greater exposure to isradipine might slow disease progression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34766657",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "erm treatment with immediate-release isradipine did not slow the clinical progression of early-stage PD.Primary Funding So",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32227247",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Recent examination of the STEADY-PD III isradipine clinical trial data concluded that early-stage Parkinson's disease (PD) participants who had longer exposure to isradipine had a significant delay in their need for symptomatic medication, as well as a lower medication burden at the end of t",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34766657",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS: Isradipine exposures did not correlate with the primary clinical outcome, changes in the antiparkinson therapy-adjusted Unified Parkinson's Disease Rating Scale parts I-III score over 36\u00a0months (Spearman rank correlation coefficient, rs : ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33460320",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " These findings suggest that greater exposure to isradipine might slow disease progressio",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34766657",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusion: Long-term treatment with immediate-release isradipine did not slow the clinical progression of early-stage P",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32227247",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, in a recently completed phase 3 clinical trial, the dihydropyridine (DHP) LTCC inhibitor isradipine failed to slow disease progression in early PD patients, questioning the feasibility of DHPs for PD therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33716705",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Recent examination of the STEADY-PD III isradipine clinical trial data concluded that early-stage Parkinson's disease (PD) participants who had longer exposure to isradipine had a significant delay in their need for symptomatic medication, as well as a lower medication burden at the end o",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34766657",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}